Medicines360 Calls on U.S. Congress to Pass Affordability is Access Act Without Delay 

Legislation will ensure people across the country can access and afford over-the-counter birth control options and plan their own reproductive lives, on their own terms  

San Francisco, CA Medicines360 applauds congressional health care leaders Sens. Patty Murray, Mazie Hirono, and Catherine Cortez Masto and Reps. Ayanna Pressley, Ami Bera, and Alexandria Ocasio-Cortez for authoring the Affordability is Access Act (S. 4347/ H.R. 7894) and leading the congressional push for equitable access to birth control. This critical legislation will require insurance companies to cover — and retailers to not interfere with access to or purchase of — birth control pills approved by the U.S. Food and Drug Administration (FDA) as safe and effective over-the-counter medicines, accessible without a prescription.  

Statement from Tina Raine-Bennett, MD, MPH, CEO at Medicines360 

“At Medicines360, our work is driven by our deep commitment to advancing a better, more equitable future for all women. We believe a critical part of ensuring that women have control over their lives and their futures is ensuring that they can access comprehensive reproductive health care, including contraception. The criteria for whether a safe, effective product should be available over the counter is first that a person be able to make correct decisions about whether or not it is appropriate for them to use a product, and second, that they are able to use the product without assistance from a provider. Women know when they need birth control and taking a daily pill is not complicated. Birth control pills that are available to women over-the-counter should be covered by insurance so they remain accessible and affordable. Medicines360 is proud to support the Affordability is Access Act, and calls on Congress to pass this important legislation without delay.”  

The Affordability is Access Act would: 

  • Ensure coverage of comprehensive preventive health services and expand coverage to include full access to oral contraception for routine, daily over-the-counter use for all. Private health insurance plans are currently required to cover all categories of U.S. Food and Drug Administration (FDA)-approved methods of contraception. The Act would ensure coverage of oral contraception that the FDA has approved or regulated for routine, daily use without a prescription.  
  • Maintain the FDA’s sole authority to determine the safety and efficacy of drugs and make them available over-the-counter without a prescription. 
  • Ensure retailers provide oral contraception without a prescription. The Act states that a  retailer that stocks oral contraception that the FDA has approved or regulated for routine, daily use without a prescription may not interfere with a consumer’s access to or purchase of such contraception.  

Medicines360’s nonprofit mission has always been about closing critical gaps in women’s health care, and ensuring that women have access to the medicines and devices they need to live their best and fullest lives. In the wake of the Supreme Court’s recent decision in Dobbs v. Jackson Women’s Health Organization, Medicines360 recommitted itself to serving women who are disadvantaged and discriminated against in the healthcare system, and vowed to strengthen its work to expand access to affordable birth control options. 

About Medicines360 

Medicines360, located in San Francisco, California, is a global nonprofit women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. For more information, visit 

Press Contact: Stacey Manley 
Vice President, Communications & Marketing    415.951.8700  

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.